Table 4.
Screens used for in vivo overlap analyses
| Cell line | Tumor type | Immune attack | Library | Sensitivity/resistance | Publication | Organism |
|---|---|---|---|---|---|---|
| B16F10 | Melanoma | GVAX + anti-PD-1 + anti-CTLA-4 + spontaneous immunity | Custom (based on in vitro pathways) | Both | Manguso et al.6 | Mus musculus |
| EMT6 | Mammary carcinoma | Spontaneous immunity | Custom (targeting immune-relevant genes) | Both | Lawson et al.5 | Mus musculus |
| Renca | Renal adenocarcinoma | anti-PD-1 + anti-CTLA-4 + spontaneous immunity | Custom (Manguso library6) | Both | Dubrot et al.3 | Mus musculus |
CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; PD-1, programmed cell death protein 1.